- Home
- ATAI vs SANA Comparison
ATAI vs SANA Comparison
Compare ATAI & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- SANA
- Stock Information
- Founded
- ATAI 2018
- SANA 2018
- Country
- ATAI Germany
- SANA United States
- Employees
- ATAI N/A
- SANA N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- SANA Medicinal Chemicals and Botanical Products
- Sector
- ATAI Health Care
- SANA Health Care
- Exchange
- ATAI Nasdaq
- SANA Nasdaq
- Market Cap
- ATAI 444.7M
- SANA 489.5M
- IPO Year
- ATAI 2021
- SANA 2021
- Fundamental
- Price
- ATAI $2.66
- SANA $3.96
- Analyst Decision
- ATAI Strong Buy
- SANA Strong Buy
- Analyst Count
- ATAI 2
- SANA 6
- Target Price
- ATAI $11.00
- SANA $10.00
- AVG Volume (30 Days)
- ATAI 5.7M
- SANA 6.2M
- Earning Date
- ATAI 08-12-2025
- SANA 08-07-2025
- Dividend Yield
- ATAI N/A
- SANA N/A
- EPS Growth
- ATAI N/A
- SANA N/A
- EPS
- ATAI N/A
- SANA N/A
- Revenue
- ATAI $1,863,000.00
- SANA N/A
- Revenue This Year
- ATAI $554.22
- SANA N/A
- Revenue Next Year
- ATAI N/A
- SANA N/A
- P/E Ratio
- ATAI N/A
- SANA N/A
- Revenue Growth
- ATAI 572.56
- SANA N/A
- 52 Week Low
- ATAI $1.03
- SANA $1.26
- 52 Week High
- ATAI $2.99
- SANA $7.40
- Technical
- Relative Strength Index (RSI)
- ATAI 62.17
- SANA 76.84
- Support Level
- ATAI $2.62
- SANA $2.60
- Resistance Level
- ATAI $2.99
- SANA $3.01
- Average True Range (ATR)
- ATAI 0.24
- SANA 0.32
- MACD
- ATAI 0.03
- SANA 0.09
- Stochastic Oscillator
- ATAI 67.01
- SANA 75.98
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.